5 Oct
2021

Amgen’s Otezla win vindicates multi-billion-dollar IP purchase

A recent district court victory – and a slew of settlements –have gone a long way to justifying the $13.4 billion Amgen paid for Otezla’s IP

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth